Curative chest re‑irradiation for thoracic cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Danish multicenter prospective cohort collecting detailed radiotherapy dose data, toxicity events, loco‑regional control, and overall survival for patients receiving curative‑intent thoracic reirradiation. The protocol requires available digital prior treatment plans (DICOM) and uses predefined dose‑accumulation methods and provisional organ‑at‑risk constraints to harmonize treatment across sites. Data will feed into national infrastructure and decision tools to support shared decision‑making and referral pathways. Four substudies will address implementation, dose constraints, outcomes, and safety to create a uniform clinical framework for reirradiation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Radiotherapy of thoracic lesion(s) (loco-regional lung cancer recurrence, new primary lung cancer, or solitary oligo metastasis) with the aim of long-term local control.
* Reirradiation type 1 or type 2, i.e. previous radiotherapy to the thorax as per ESTRO-EORTC consensus definition of reirradiation \[Andratschke 2022\]. For the sake of this study, multiple treatments to the lungs will be classified as type 2 reirradiation.
* Verification of malignancy based on biopsy. If no biopsy is available, the decision of reirradiation should be agreed upon in a multidisciplinary conference.
* Available digital dose plan(s) from former radiotherapy course(s) (DICOM files) - note that multiple re-treatments are allowed.
* Adequate lung function to tolerate treatment, at the discretion of the treating physician.
* Ability to complete a radiotherapy course with the aim of local control.
* ECOG Performance status 0-2.
* Estimated life expectancy ≥ 6 months
* Age ≥18 years
* Signed informed consent

Exclusion Criteria:

* Uncontrolled other malignancy.
* The primary and the reirradiation treatment may not be quasi-simultaneous (i.e. the two treatments should be planned independently)
* Pregnancy
* Radiotherapy to a minimum CTV mean dose of 45 Gy for SCLC and 50 Gy for NSCLC and oligometastatic lesions. Treatment schedule according to local protocols and treating physician preference.

Where it's running

• Aarhus University Hospital
  Aarhus, Jutland, Denmark Recruiting

Study contacts

• Study coordinator: Stine O Fredslund, MD, PhD
• Email: stin.fred@auh.rm.dk
• Phone: +45 28713076

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LUCINAE Registry: Thoracic Cancers in Pregnancy

  This international registry collects data to see how thoracic cancers, including lung cancer, are managed and what outcomes look like for pregnant people and their babies.

  Recruiting at 4 sites Oncology Institute of Southern Switzerland · Baden and 3 other locations · NCT07699861

• Heart-friendly medicines to protect chest-area cancer patients from radiation damage

  This Phase 2 trial tests whether taking atorvastatin and lisinopril can reduce heart damage in adults with chest-area cancers who receive radiation therapy.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07685938

• Long-term clinical and tissue data collection for people with thoracic cancers

  This project will collect medical records, imaging, quality-of-life information, and tissue/blood samples over time from adults with thoracic cancers to try to find factors that predict outcomes.

  Recruiting at 11 sites Dutch Society of Physicians for Pulmonology and Tuberculosis · Ede, Gelderland and 22 other locations · NCT06996249

• TNG462 combined with RAS inhibitors or chemotherapy for MTAP‑loss pancreatic and RAS‑mutant lung cancer

  This trial will test whether taking oral TNG462 together with RAS inhibitors or standard chemotherapy is safe and helps people with MTAP‑loss pancreatic cancer or RAS‑mutant non‑small cell lung cancer.

  Recruiting at 18 sites Phase 1/2 Tango Therapeutics, Inc. · Scottsdale, Arizona and 17 other locations · NCT06922591

• Stereotactic radiotherapy for centrally and ultra-centrally located lung tumors

  This study is testing a type of targeted radiation therapy for patients with lung tumors located in tricky spots to see how safe and effective it is.

  Recruiting at 5 sites Copenhagen University Hospital, Rigshospitalet · Aalborg and 5 other locations · NCT05354596

• Registry of patients treated with heavy particle therapy for cancer

  This study is collecting information from cancer patients treated with advanced heavy particle therapy to see how well it works and what side effects it might cause.

  Recruiting CNAO National Center of Oncological Hadrontherapy · Pavia · NCT05203250

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.